Table 3.

Radiosensitivity (D0) and RBE of the MDA-MB-231cell line under different exposure and DNA repair pathway inhibition conditions

Agent, manipulationD0 (Gy)RBEa
213Bi-Rituximab (irrelevant Ab)0.843.8
213Bi-Cetuximab0.873.7
213Bi-Cetuximab, siRNA scrambled control0.694.7
213Bi-Cetuximab, siRNA DNA-PKcs-/DNA-PKcs-0.378.6
213Bi-Cetuximab, siRNA BRCA1-/BRCA1-0.2115.6
  • aRBE is reported using 37% cell survival as the biologic endpoint and Cs-137 gamma rays as the reference radiation.